來蘇之望丨張小田教授:創(chuàng)新靶向聯(lián)合免疫,有望攻下晚期胃癌治療“堡壘”( 三 )
參考資料:
[1] Shen L, Lu M, Chen ZD, et al. Phase II trial of surufatinib plus toripalimabfor disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junctionadenocarcinoma.2021 ASCO. e16040.
[2] MoehlerM., Shitara K., Garrido M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo)versus chemo as first-line (1L) treatment for advanced gastriccancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma(EAC): first results of the CheckMate 649 study. Ann Oncol. 2020;31:S1191.
[3] FukuokaS, Hara H, Takahashi N, et al. Regorafenib Plus Nivolumab in Patients WithAdvanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, andDose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun20;38(18):2053-2061.
[4] Lu M,Cao YS, Gong JF,et al. A Phase I Trial of Surufatinib plus Toripalimab inPatients with Advanced Solid Tumor. AACR 2020. Abstract No. 9563.
*此文僅用于向醫(yī)學(xué)人士提供科學(xué)信息 , 不代表本平臺觀點(diǎn)
【來蘇之望丨張小田教授:創(chuàng)新靶向聯(lián)合免疫,有望攻下晚期胃癌治療“堡壘”】
推薦閱讀
- EHA中國之聲丨張磊教授:我國兒童ET的現(xiàn)狀及特點(diǎn),一項真實(shí)世界研究
- 來蘇之望|中國“核”心大咖共話甲狀腺癌診療現(xiàn)狀,民族藥物譜寫臨床治療新格局
- 中國隊|突發(fā)官宣3連!敘利亞5大原則不來蘇州,主動改賽死磕中國隊,補(bǔ)招2人
- 籃網(wǎng)隊|巴薩顫抖嗎?馬競帝星:感謝巴薩送來蘇神,我們的大門已向梅西敞開!
